



**Supplementary figure 1. Plot of ADCC assay reports comparing 6 lots of hu14.18K322A in comparison to dinutuximab (unituxin).** M21 cells, expressing the GD2 cell surface epitope, served as the target cells. Engineered Jurkat cells, with a cell-surface FcγRIIIa (V158) receptor, served as the effector cells. Crosslinking of the two cells by either hu14.18K322A or dinutuximab led to gene transcription through NFAT (nuclear factor of activated T-cells) with subsequent NFAT response element (RE) driving expression of a firefly luciferase reporter protein. The luciferase reporter substrate was converted to a luminescent product and quantified as relative luminescence units (RLU) on a plate reader.